Dr Hamid Ghareh-Hassanlou and his wife Farzaneh were convicted after a trial on 30 November. The radiologist is now facing execution. International doctors and medical associations are now mobilising to prevent the execution.
The inhibitor was highly effective in severe alopecia areata with a high % of satisfied or very satisfied patients.
Secukinumab achieved a clinical response in over 40% of hidradenitis suppurative patients and reduced abscesses and pain, and improved quality-of-life.
Chronic stress releases cortisol. Studies show that this increases cravings for high-calorie, sweet, fatty and processed foods. A challenge for many overweight people.
An analysis of 811 surveys shows nearly half of psoriasis patients have psoriatic lesions around the genital region and other areas of sexual interest.
Are you a rock fan? According to a study, if "Highway to Hell" riffs at high volume in the operating theatre, there's a good prognosis!
Significantly more patients on nalbuphine achieved at least a 4-point decrease on the worst itch (WI-) numeric rating scale (NRS), QoL rose, and skin lesions improved.
Improvement seen in progression-free survival and ORR by the selective KRAS G12C inhibitor over docetaxel in previously treated KRAS G12C-mutated NSCLC.
Difelikefalin leads to rapid decrease in pruritus in notalgia paresthetica, a very common, underdiagnosed condition with a lack of treatment possibilities.
KEEPsAKE 1 and 2 trials demonstrated high efficacy of the IL-23 blocker risankizumab in adult patients with active psoriatic arthritis independent of previous therapy.
A local and oral preparation of polypodium leucotomos extract led to clinical reversal of actinic keratosis lesions at 12 months.
Dr. Robert McMickle, an emergency physician at Harbor UCLA Medical Center in Los Angeles, delves into the topic of lightning injuries.
A trial on colonoscopy for colorectal cancer prevention showed that a physician invitation for a screening check-up reduced incidence but not mortality.
A new study shows over 80% of primary endpoint reach of clear or almost clear skin, according to the Investigator's Global Assessment at week 8.
Piclidenoson reached its primary endpoint with a statistical difference over placebo while showing a very good safety profile but did not outperform apremilast.
Deucravacitinib performed with durable efficacy. Up to week 112, results in various outcome measures were consistent with those at week 52.
Biologics were recently approved for hidradenitis suppurativa, but many patients who do not respond efficiently experience a significant disease burden.
Excessive salt and alcohol consumption can trigger unpleasant events. One of these is the little-noticed Holiday Heart Syndrome.
Associate Prof. Vaghefi discusses AI retina scan algorithms, how the retina can detect other health issues, and how the retinal tech was deployed in rural India.
Ritlecitinib sustained efficacy in treatment up to month 36 without new safety signals. Patient-reported outcomes improved already after 3 months.